
Academic Office:
LSUHSC School of Medicine
Department of Pharmacology
CSRB 533 Bolivar Street
New Orleans, LA 70112
Bio
Dr. Paul has more than 30 years of research xperience in Pharmacology and Neurology. He has also taught courses in medical, dental and related professions for pain management. Dr. Paul is the Chief Science Officer of Oleander Medical Technologies and co-inventor of Targeted Osmotic Lysis (TOL).
Education
University of Cincinnati, Cincinnati, OH B.A.
1980 Physiological Psychology
U. British Columbia, Vancouver, B.C., Canada M.A. 1984
Biopsychology
CIBA-Geigy Pharmaceuticals, Basel, Switz. Praktikant 1984 Biology/Pharmacology
U. British Columbia, Vancouver, B.C., Canada Ph.D. 1988
Biopsychology
Memorial Sloan-Kettering Cancer Center, NY, NY Post-doc 1990 Pharmacology/Neurology
Awards & Patents
Awards
2015 LSU Health Sciences Center Innovators Award
2020 Allen A. Copping Award for Excellence in Teaching
Patents
- US Patent #6,864,271. Bazan, N., Paul, D., Sunkel, C. and Alvarez-Builla, J. Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives. Issued March 8, 2005.
- US Patent #7,064,140 Bazan, N., Paul, D., Sunkel, C. and Alvarez-Builla, J. “Synergistic Combinations Including N-Acylated 4-Hydroxyphenylamine Derivatives and Caffeine.” Issued June 20, 2006.
- US Patent #8921320 Paul, DJ and Gould, HJ III “Targeted osmotic lysis of cancer cells.” Issued December 30, 2014.
- Japan Patent #5,945,597 Paul, DJ and Gould, HJ III “Targeted osmotic lysis of cancer cells.” Issued June 3, 2016.
- Australia Patent #989,841 Paul, DJ and Gould, HJ III “Targeted osmotic lysis of cancer cells.” Issued September 30, 2016.
- WIPO WO2019/040122 Bazan, N., Bazan, H., Alvarez-Builla Gomez, J., Paul, D., Garcia, CB. “Compositions and methods for ameliorating pain.” Issued February 28, 2019.
- WIPO WO2019/018207 Al, Paul, DJ and Gould, HJ III “Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients” issued 1/24/2019. U.S. Allowed 4/5/2023
Publications
Paul D, Gately L, Sims A, Gould HJ. Use of Targeted Osmotic Lysis for the Treatment of Cutaneous Squamous Cell Carcinoma. Ann Oncol Case Rep. 2025; 5(1): 1028
Gould HJ, Dahiya RS, Sims A, Paul D. Use of Targeted Osmotic Lysis for the Treatment of Malignant Melanoma: Case Report. Ann Oncol Case Rep. 2025; 5(1): 1027.
Scahill, S.D., Sherman, K.J., Guidry, J.J., Walkowski, W., Ray, D.B., Jones D.H., Gould, H.J. III, Paul, D. (2023) In vitro Characterization of a novel murine model of cancerous progression. Advances in Cancer Biology – Metastasis 7: 100101. https://doi.org /10.1016/j.adcanc.2023.100101
Gould, H.J. and Paul, P. (2022) Targeted Osmotic Lysis: A Novel Approach to Targeted Cancer Therapies. Biomedicines:10, 838. https://doi.org/10.3390/biomedicines10040838
Gould, H.J. III, Edenfield S.I., Miller, P.R., Sherman, K.J., Melius, B., Whitney, A., Hunter, R.P., Del Piero, F., Tracey, D. and Paul, D. (2022) The role of targeted osmotic lysis in the treatment of advanced carcinoma in companion animals: A case series. Case Rep Vet Med. 2022:2747108 doi: 10.1155/2022/2747108
Gould, H.J. III, and Paul, D. (2022) Cancer as a Channelopathy—Appreciation of Complimentary Pathways Provides a Different Perspective for Developing Treatments. Cancers 14:4627. doi:10.3390/cancers14194627
Edenfield, S., Sims, A.M., Porretta, C., Gould, H.J., Paul, D. (2022) Effect of Cell Cycle on Cell Surface Expression of Voltage- Gated Sodium Channels and Na+,K+-ATPase. Cells
Gould, H.J. III, Miller, P.R., Edenfield, S.I., Sherman, K.J., Brady, C.K., and Paul, D. (2021) Emergency use of targeted osmotic lysis for the treatment of a patient with aggressive, late-stage squamous cell carcinoma of the cervix. Curr Oncol. 28:2115-2122. doi: 10.3390/curroncol28030196.
Paul, D., Maggi, P., del Piero, F., Scahill, S.D., Sherman, K.J., Edenfield, S., and Gould, H.J., III (2020) Targeted osmotic lysis of highly invasive breast carcinomas using a pulsed magnetic field and pharmacological blockade of voltage-gated sodium channels. Cancers 12: 1420, doi: 10.3390/cancers12061420.
Bazan, H.A., Bhattacharjee, S., Burgos, C., Recio, J., Abet, V,., Pahng, A.R., Bokkyoo, J., Heap, J., Ledet, A.J., Gordon, W.C., Edwards, S., Paul, D., Alvarez-Builla, J., Bazan, N.G. (2020) A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis. Eur. J. Med. Chem. DOI: 10.1016/j.ejmech.2020.112600
Gould, H., Norleans, J., Ward T.J., Reid, C. and Paul, D. (2018) Selective Lysis of Breast Carcinomas by Simultaneous Stimulation of Sodium Channels and Blockade of Sodium Pumps. Oncotarget 9: 15606-15615.
PubMed Publication Search
Research
We are developing a novel method for treating advanced carcinomas that we call targeted osmotic lysis, or TOL. Carcinomas over-express voltage sodium channels by 10- to 20-fold. Others have blocked these channels to slow metastasis and invasiveness. Instead, we activate the channels with a pulsed electric field while simultaneously blocking the sodium pumps that return the sodium to the extracellular space with a cardiac glycoside drug. This results in a very high intracellular sodium concentration. Because water follows sodium, the cancer cells swell and lyse. Normal cells with fewer sodium channels and less intracellular sodium do not lyse. We have evidence that this will work in breast, lung, prostate, pancreatic, mast cell, colon, orofacial, and cervical cancers. We are currently working on translational studies to increase efficacy and progress towards clinical trials.